Clinical trials: Hepatic Cirrhosis
Exocrine Pancreatic Insufficiency
Prevalence of Exocrine Pancreatic Insufficiency in Patients With Decompensated Cirrhosis
Exocrine pancreatic insufficiency (EPI) is the inability of the pancreas to perform a normal digestive function. The prevalence of IPE in patients with decompensated hepatic cirrhosis (HC) is unknown and most published series are…
- Trial name
- (EPIIHC) (NCT03236038)
- Testing
- Labeled triolein urea breath test
- Where
- Spain
- Volunteers
- 125 people
- Sponsor
- Corporacion Parc Tauli
End Stage Liver Disease, Decompensated Cirrhosis of Liver
Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)
This is a comparative effectiveness study of two pragmatic models aiming to introduce palliative care for end stage liver disease patients. The 2 comparators are: Model 1: Consultative Palliative Care (i.e.
- Trial name
- PAL-LIVER (NCT03540771)
- Testing
- Palliative Care
- Where
- 19 sites in United States
- Volunteers
- 1,494 people
- Sponsor
- Albert Einstein Healthcare Network
Cirrhosis, Liver, Volume Overload
Compare the Diuretic Effect With Furosemide vs Furosemide and Albumin Combined in Cirrhotic Patients
A common complication of the progression of cirrhosis is fluid retention (ascites, edema, or pleural effusion). Loop diuretics are the treatment of choice for fluid retention in cirrhotic patients; however, many of these patients…
- Conditions
- Cirrhosis, Liver, Volume Overload, Fluid Overload
- Trial name
- NCT04216784
- Testing
- Furosemide Injection, Albumin Human
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Rush University Medical Center
Liver Fibrosis
Prediction of Significant Liver Fibrosis
The deep learning method based on convolutional neural network (CNN) was used to extract the relevant features of liver fibrosis classification from the multi-modal information of digital pathological sections, clinical…
- Trial name
- PSLF (NCT06509230)
- Where
- China
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Huang Haijun
Portopulmonary Hypertension, Pulmonary Hypertension
Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension
The purpose of this study is to evaluate the efficacy and safety of the combination of ambrisentan and tadalafil in reducing mPAP to below 35mmHg in patients with moderate to severe Portopulmonary Hypertension (POPH) as a means…
- Conditions
- Portopulmonary Hypertension, Pulmonary Hypertension, Cirrhosis, Liver
- Trial name
- NCT03309592
- Testing
- Ambrisentan Pill, Tadalafil Pill
- Where
- United States
- Sponsor
- Ochsner Health System
Liver Failure, Cirrhosis
Improvement of Liver Function in Liver Cirrhosis Patients After Autologous Mesenchymal Stem Cell Injection:a Phase I-II Clinical Trial
The methods for separation of mesenchymal stem cell were established in 2001. These cells can differentiate to osteocytes, hepatocytes, chondrocytes, myocytes and etc,.
- Trial name
- NCT00420134
- Testing
- injection of progenitor of hepatocyte drived from Mesenchymal stem cell
- Where
- 2 sites in Iran
- Volunteers
- 30 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Cancer of Liver, Cancer of Colon
Getting To Implementation: Improving Cancer Screening for Veterans
Gastrointestinal cancers such as colon cancer and liver cancer cause many deaths in the US. Testing could catch these cancers early, helping people live longer.
- Conditions
- Cancer of Liver, Cancer of Colon, Cirrhosis
- Trial name
- GTI (NCT06458998)
- Testing
- Patient Navigation, Implementation Facilitation
- Where
- United States
- Volunteers
- 30,300 people
- Sponsor
- University of Pittsburgh
Other Surgical Procedures
Safety and Efficacy of Stem Cell Transplantation for Treatment of Liver Cirrhosis
Mainstream of current treatment of liver cirrhosis is liver transplantation, but there are high cost, risk and immune rejection and other issues.
- Trial name
- NCT01491165
- Testing
- stem cell transplantation through interventional procedures
- Where
- China
- Volunteers
- 75 people
- Sponsor
- General Hospital of Chinese Armed Police Forces
Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH)
The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF
The main purpose of this study is to compare the effectiveness of various non-invasive elastography techniques at determining liver stiffness measures in human subjects.
- Conditions
- Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Liver Fibroses, Liver Steatoses
- Trial name
- NCT04682600
- Testing
- Liver Incytes System
- Where
- United States
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Sonic Incytes
Short Bowel Syndrome, Intestinal Failure
Effect of Parenteral Support on FibroScan in Short Bowel Syndrome
Home Parenteral Support (HPS) is a life-sustaining treatment for patients with short bowel syndrome and intestinal failure. This study aims to investigate how administration of parenteral support affects FibroScan results in…
- Conditions
- Short Bowel Syndrome, Intestinal Failure, Liver Diseases
- Trial name
- NCT07206004
- Testing
- Fibroscan
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Liver Cirrhosis
Effects on Liver Cirrhotic Patients' by a Nurse-led Clinic
This study compare the effects of traditional follow-up by physician with a combined follow-up alternately by physician and nurse-led clinic. The main variable is; health related quality of Life.
- Trial name
- NCT02957253
- Testing
- risk factors, self-care, nutrition
- Where
- 6 sites in Sweden
- Volunteers
- 167 people
- Sponsor
- Uppsala University
Liver Cirrhosis
AFP - L3% and DCP as Screening Marker for a Hepatocellular Carcinoma in Patients With Cirrhosis of the Liver
Hepatocellular carcinoma (HCC) is one of the tumors with a rising incidence worldwide. The aim of this trial is to improve the detection of early HCC nodules in the liver.
- Trial name
- NCT01361061
- Where
- 2 sites in Germany
- Volunteers
- 450 people
- Sponsor
- University Hospital Freiburg
Non-B Non-C Liver Cirrhosis
Evaluation of Non-B Non-C Liver Cirrhosis in A EL-Rajhi Assuit University Hospital: A Retrospective-Prospective Study
To study the etiologies of patients diagnosed as non-B, non-C liver cirrhosis (NBNC-LC). To describe the different patient's outcomes.
- Trial name
- NCT05314270
- Testing
- Diagnostic tests
- Volunteers
- 100 people
- Sponsor
- Assiut University
Hepatitis C
Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis
The purpose of the study is to determine if the combination of Daclatasvir, Sofosbuvir and Ribavirin for 12 or 16 weeks is safe and effective in the treatment of Genotype 3 Chronic Hepatitis C (HCV) in patients with advanced…
- Trial name
- NCT02319031
- Testing
- Daclatasvir, Sofosbuvir, Ribavirin
- Where
- 10 sites in Australia, France
- Volunteers
- 53 people
- Sponsor
- Bristol-Myers Squibb
Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC)
The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
Cholestatic liver diseases are characterized by jaundice, pruritus, and elevated levels of alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT).
- Conditions
- Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Atopic Dermatitis (AD)
- Trial name
- NCT07678645
- Testing
- Upadacitinib 15 MG
- Where
- China
- Volunteers
- 44 people
- Sponsor
- RenJi Hospital
Portal Hypertension Related to Cirrhosis
EUS-guided Response Assessment to NSBB
The goal of this clinical trial is to learn if endoscopic ultrasound (EUS)-guided portal pressure measurement can determine the treatment response to non-selective beta-blockers (NSBB) in patients with cirrhosis and clinically…
- Trial name
- NCT06513195
- Testing
- endoscopic ultrasound-guided portal pressure measurement
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Liver Cirrhosis, Biliary
Physical Therapy for Liver Cirrhosis
Patients with liver cirrhosis have severe physical deconditioning. Aim: To compare between the effect of neuromuscular electric stimulation(NMES) and exercises (EX)on treatment of patients with liver cirrhosis.
- Trial name
- NCT04629456
- Testing
- neuromuscular electric stimulation, Exercises
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
PBC, Primary Biliary Cholangitis
Swiss Primary Biliary Cholangitis Cohort Study
Research project in which biological material is sampled and health-related medical data is collected. In addition, already existing health-related medical data are used for further research. Coded data are used.
- Trial name
- NCT03146910
- Where
- 13 sites in Switzerland
- Volunteers
- 500 people
- Sponsor
- Fondazione Epatocentro Ticino
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis
This study will evaluate the safety, feasibility, and preliminary effects of S-adenosyl-L-methionine (SAMe) compared with placebo in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis.
- Trial name
- SAMeMASLDc-02 (NCT07495995)
- Testing
- S-adenosyl-L-methionine (SAMe), Placabo
- Volunteers
- 94 people
- Sponsor
- Cedars-Sinai Medical Center
Non Alcoholic Steatohepatitis, Hyperuricemia
Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuricemia
This study aims at evaluating and comparing the protective outcomes of using Febuxostat versus Vitamin E in Hyperuricemia non-alcoholic steatohepatitis patients without cirrhosis.
- Trial name
- NCT05574036
- Testing
- Febuxostat 80 MG Oral Tablet, vit E
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Tanta University